



PharmSource® Lead Sheet

New business opportunities for companies serving pharma

©2009 PharmSource Information Services Inc.

[Contact Information](#) [License Information](#)

FOR WEEK OF:

02-15-2009

[\[Export All\]](#) [\[Clear All\]](#)

Julia's Profile

Products in Development

Products in Development ●

Product Acquisitions ●

Corporate Finance ●

Other Sponsor Events ●

Key Appointments ●

Downloads

Preferences

Comments/Questions?

Full Database Search

Qualifying Info Search

[PRINTER FRIENDLY](#)

[\[Export All\]](#) [\[Clear All\]](#)

[Export help](#)

Preclinical

Export

Company: [ActoGenix NV](#)

HQ Location: Zwijnaarde , Belgium

Product: AG013

Dosage Form: Unknown

Nature of API: Peptide - Process unknown

Therapeutic Area: Oncology - Other
Anti-inflammatory

Comment: ActoGenix reports plans to file an IND within the next few months for a Phase Ib trial with AG013, a treatment of oral mucositis in cancer patients. AG013 delivers a specific human trefoil factor, a class of peptides that protect the gastrointestinal tissues against mucosal damage.

CMC R&D Contact: [Patrick Dhaese, PhD](#)

Research contact: [Sabine Neiryndck, PhD](#)

Research contact: [Pieter Rottiers, PhD](#)

Research contact: [Bernard Coulie, MD, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Alnylam Pharmaceuticals](#)

HQ Location: Cambridge, MA

Product: Claudin-3 RNAi

Dosage Form: Unknown

Nature of API: Nucleic acid - RNA

Therapeutic Area: Oncology - Other

Comment: Alnylam reports positive preclinical data using small interfering RNAs (siRNAs) to suppress tumor growth. Lipidoid formulations of siRNAs were used to target the claudin-3 protein that suppressed ovarian tumor growth and metastases.

Preclinical contact: [Muthiah Manoharan, PhD](#)

Clinical research contact: [John A. Schmidt, Jr., MD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Phase I

Export

Company: [Amarillo Biosciences, Inc.](#)
HQ Location: Amarillo, TX
Product: Interferon alpha
Dosage Form: Oral solid
Nature of API: Biologic - Protein
Therapeutic Area: Immunomodulator
Antiviral
Liver disease

Comment: Amarillo's Taiwanese partner, CytoPharm, receives approval to initiate a Phase II trial for interferon alpha (IFNa) in chronic hepatitis C patients. IFNa is administered as orally dissolving lozenges. IFNa is not a recombinant protein; it is produced by human cells. The trial is expected to enroll 165 patients in Taiwan and start in Q2 of 2009.

Corporate: [Joseph M. Cummins](#)

Clinical research contact: [Martin Cummins](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Cubist Pharmaceuticals, Inc.](#)
HQ Location: Lexington, MA
Product: CB-183,315
Dosage Form: Oral - Unspecified
Nature of API: Peptide - Process unknown
Chemical - Antibiotic
Therapeutic Area: Gastrointestinal
Antibacterial

Comment: Cubist initiates a Phase I trial for CB-183,315, an orally administered lipopeptide for the treatment of C. difficile-associated diarrhea (CDAD). Preclinical studies have demonstrated in vivo efficacy in a hamster CDAD model and an ability to prevent spores from generating more bacteria. In addition, the drug does not appear to cause cell lysis or the release of C. difficile toxins.

Research contact: [Steven Gilman, PhD](#)

Clinical research contact: [Santosh J. Vetticaden, MD, PhD](#)

Corporate: [Robert J. Perez](#)

Manufacturing and packaging contact: [Lindon M. Fellows](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Cubist Pharmaceuticals, Inc.](#)
HQ Location: Lexington, MA
Product: CB-182,804
Dosage Form: Parenteral - Unspecified

Nature of API: Chemical - Antibiotic
Therapeutic Area: Antibacterial
Comment: Cubist initiates a Phase I trial with CB-182,804, an intravenous antibiotic for the treatment of multi-drug resistant (MDR) Gram-negative infections. In preclinical studies, CB 182,804 has demonstrated an ability to interact with Gram-negative cell membranes and rapidly shut down bacterial DNA, RNA and protein synthesis.

Research contact: [Steven Gilman, PhD](#)
 Clinical research contact: [Santosh J. Vetticaden, MD, PhD](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export

Company: [Genaera Corporation](#)
HQ Location: Plymouth Meeting, PA
Product: Trodusquemine (MSI-1436)
Dosage Form: Parenteral - Unspecified
Nature of API: Chemical - Normal potency
Therapeutic Area: Diabetes
Nutrition and obesity
Comment: Genaera reports positive preliminary data from a Phase Ib trial of trodusquemine in overweight and obese type 2 diabetics. Trodusquemine regulates food intake, weight gain and blood sugar by inhibiting the protein tyrosine phosphatase 1B, which controls the function of leptin and insulin pathways.

Research contact: [Henry Wolfe, PhD](#)
 Clinical research contact: [Michael Gast, MD, PhD](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export

Company: [Inspiration Biopharmaceuticals](#)
HQ Location: Laguna Niguel, CA
Product: IB1001
Dosage Form: Parenteral - Unspecified
Nature of API: Biologic - Recombinant protein
Therapeutic Area: Coagulation and blood formation
Comment: Inspiration Biopharmaceuticals initiates a Phase I trial with IB1001 for the control and prevention of hemorrhagic episodes in patients with hemophilia B. The product is an intravenous recombinant Factor IX that is produced with Inspiration's recombinant protein manufacturing technology.

Research contact: [Ed Gomperts, MD](#)
 Clinical research contact: [Martin Lee, PhD](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

<input type="checkbox"/> Export	Company: Lux Biosciences, Inc.
	HQ Location: Multiple
	Product: LX214
	Dosage Form: Liquid - Sterile
	Nature of API: Chemical - Normal potency
	Therapeutic Area: Ophthalmology Anti-inflammatory
	Comment: Lux Biosciences initiates a Phase I trial with LX214 for keratoconjunctivitis sicca. LX214 is a clear topical eye drop formulation of voclosporin, a calcineurin inhibitor.
	<input type="checkbox"/> Corporate: A. Clark Atwell
	<input type="checkbox"/> Clinical research contact: Eddy Anglade, MD
	<input type="checkbox"/> Research contact: Sidney L. Weiss
Print Lead	Email Lead
	[Back to Top]

<input type="checkbox"/> Export	Company: Nektar Therapeutics
	HQ Location: San Carlos, CA
	Product: NKTR-105 (PEG-docetaxel)
	Dosage Form: Parenteral - Unspecified
	Nature of API: Chemical - Cytotoxic
	Therapeutic Area: Oncology - Chemotherapy
	Comment: Nektar initiates dosing in a Phase I trial for NKTR-105 in approximately 30 patients with refractory solid tumors who have failed all prior available therapies. NKTR-105 is a PEGylated conjugate of docetaxel, an antineoplastic agent that disrupts the microtubular network in cells. NKTR-105 is being developed to treat multiple solid tumor types via intravenous administration.
	<input type="checkbox"/> Corporate: Howard W. Robin
	<input type="checkbox"/> Preclinical contact: Randall Moreadith, MD, PhD
Print Lead	Email Lead
	[Back to Top]

<input type="checkbox"/> Export	Company: TorreyPines Therapeutics
	HQ Location: La Jolla, CA
	Product: NGX426
	Dosage Form: Oral solid
	Nature of API: Chemical - Normal potency
	Therapeutic Area: Analgesic - Non-narcotic Neurology
	Comment: TorreyPines successfully completes a Phase I trial for NGX426 as a treatment for acute and chronic pain conditions. NGX426 is an oral prodrug of tezampanel, an AMPA/kainate receptor antagonist. TorreyPines will seek funding and strategic

alternatives to proceed with a Phase II trial.

Corporate: [Evelyn Graham](#)

Clinical research contact: [Sue Mellberg](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Vical, Inc.](#)

HQ Location: San Diego, CA

Product: Vaxfectin-formulated pandemic flu vaccine

Dosage Form: Parenteral - Unspecified

Nature of API: Biologic - DNA - Plasmid
Biologic - Vaccine - DNA

Therapeutic Area: Vaccine (infectious target)

Comment: Vical reports positive results from a Phase I trial for Vaxfectin-formulated pandemic flu vaccine. Vaxfectin is a novel cationic lipid formulation optimized to increase the immune response to plasmid DNA vaccines. The trial evaluated monovalent and trivalent Vaxfectin-formulated H5N1 pandemic influenza DNA vaccines.

Manufacturing and packaging contact: [Kevin Bracken](#)

Research contact: [Alain P. Rolland, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Phase II

Export

Company: [arGentis Pharmaceuticals, LLC](#)

HQ Location: Memphis, TN

Product: ARG201

Dosage Form: Oral - Unspecified

Nature of API: Biologic - Protein

Therapeutic Area: Immunomodulator

Comment: arGentis reports that ARG201 has received orphan drug designation in the EU for the treatment of diffuse systemic sclerosis (SSc). ARG201 is an immunotherapy that induces low-dose oral immune tolerance in SSc patients, causing downregulation of the body's autoimmune response. The product has completed a Phase II trial for this indication.

Corporate: [Tom I. Davis](#)

Corporate: [Edward \(Ted\) J. Townsend III](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Genentech, Inc.](#)

HQ Location: South San Francisco, CA

Product: GDC-0449

Dosage Form: Oral – Unspecified
Nature of API: Chemical - Normal potency
Therapeutic Area: Oncology - Other
Comment: Genentech initiates a Phase II trial with GDC-0449 for metastatic or locally advanced basal cell carcinoma. Created under a collaborative agreement with Curis, GDC-0449 is an orally administered small molecule Hedgehog antagonist. A Phase II trial was initiated in December 2008 for patients with ovarian cancer in second or third complete remission.

Research contact: [Richard H. Scheller, PhD](#)
 Research contact: [Susan Desmond-Hellmann, MD](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export

Company: [Novavax, Inc.](#)
HQ Location: Rockville, MD
Product: Influenza VLP vaccine
Dosage Form: Parenteral - Unspecified
Nature of API: Biologic - Vaccine - Recombinant
Therapeutic Area: Vaccine (infectious target)
Comment: Novavax reports positive data from a Phase I/IIa trial with its influenza virus-like particle (VLP) vaccine. The product is comprised of hemagglutinin, neuraminidase and matrix proteins of the H5N1 A/Indonesia strain.

Research contact: [Gale E. Smith, PhD](#)
 Clinical research contact: [Penny Heaton, MD](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export

Company: [Oxygen Biotherapeutics, Inc.](#)
HQ Location: Costa Mesa, CA
Product: Oxycyte
Dosage Form: Parenteral - Unspecified
Nature of API: Chemical - Normal potency
Therapeutic Area: Cardiovascular
Other
Oncology - Other
Neurology
Stroke
Comment: Oxygen plans to initiate a Phase II trial in Switzerland for Oxycyte as a treatment for traumatic brain injury. The product is a perfluorocarbon-based blood substitute and therapeutic oxygen carrier. Oxycyte is being developed to treat stroke, heart attack and cancer patients, for use as a blood substitute and in organ preservation.

Corporate: [Richard Kiral](#)

Corporate: [Chris Stern](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Sanofi-aventis](#)

HQ Location: [Multiple](#)

Product: C. difficile vaccine

Dosage Form: Parenteral - Unspecified

Nature of API: Biologic - Vaccine - Inactivated

Therapeutic Area: Vaccine (infectious target)

Comment: Sanofi-aventis initiates a Phase II trial with a toxoid vaccine for C. difficile-associated diarrhea. The vaccine uses inactivated C. difficile toxins. The Phase IIb trial involves about 600 participants with acute C. difficile infection at about 30 centers across the UK.

Research contact: [Christian Lajoux](#)

Clinical research contact: [Jean-Pierre Lehner](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Sanofi-aventis](#)

HQ Location: [Multiple](#)

Product: Dengue fever vaccine

Dosage Form: Parenteral - Unspecified

Nature of API: Biologic - Vaccine

Therapeutic Area: Vaccine (infectious target)

Comment: Sanofi Pasteur, the vaccines division of Sanofi-aventis, commences a Phase II pediatric clinical trial with its tetravalent dengue fever vaccine. The study will evaluate the vaccine's efficacy and will be conducted in Thailand. The company is collaborating with Mahidol University of Thailand, the Ministry of Public Health and the Pediatric Dengue Vaccine Initiative.

Research contact: [Christian Lajoux](#)

Clinical research contact: [Jean-Pierre Lehner](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Shionogi and Co., Ltd.](#)

HQ Location: Osaka, Japan

Product: S-2367

Dosage Form: Oral solid

Nature of API: Chemical - Normal potency

Therapeutic Area: Nutrition and obesity

Comment: Shionogi reports positive results for a Phase IIb trial with S-2367 for the treatment of obesity. The compound is a slow-acting anti-obesity agent that demonstrates a sustained

antagonistic CNS effect. The trial included 1,566 obese subjects across 80 centers in the US.

Corporate: [Isao Teshirogi, PhD](#)

Corporate: [Hitoshi Maeda](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Phase III

Export

Company: [Amgen Inc.](#)

HQ Location: Thousand Oaks, CA

Product: Motesanib (AMG 706)

Dosage Form: Oral – Unspecified

Nature of API: Chemical - Normal potency

Therapeutic Area: Oncology - Other

Comment: Amgen resumes a Phase III trial with motesanib for the treatment of patients with non-small cell lung cancer following a three-month enrollment suspension. The compound demonstrates the ability to interfere with pathways associated with tumor angiogenesis.

Research contact: [Roger Perlmutter, MD, PhD](#)

Sourcing and Supply Chain contact: [Narayan Balachandran](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [GlaxoSmithKline](#)

HQ Location: [Multiple](#)

Product: Syncria (albiglutide)

Dosage Form: Parenteral - Unspecified

Nature of API: Peptide - Biologic

Therapeutic Area: Diabetes

Comment: GSK initiates a Phase III trial with Syncria for the treatment of type 2 diabetes. Syncria is a biological, injectable form of human GLP-1, a peptide that acts throughout the body to help maintain normal blood-sugar levels and to control appetite. The trial will enroll more than 4,000 patients.

Manufacturing and packaging contact: [David Pulman, PhD](#)

Research contact: [Moncef Slaoui](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Teva Pharmaceutical Industries Ltd.](#)

HQ Location: Petach Tikva, Israel

Product: Laquinimod (SAIK-MS)

Dosage Form: Tablet

Nature of API: Chemical - Normal potency

Therapeutic Area: Neurology
Immunomodulator

Comment: Teva and collaborative partner Active Biotech report that oral laquinimod has received fast track status for the treatment of relapsing-remitting multiple sclerosis. An immunomodulatory agent, the product is currently in Phase III trials for multiple sclerosis.

Research contact: [Ben-Zion Weiner, PhD](#)

Marketing and sales: [Michael Netz](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Terminated in Phase II or III

Export

Company: [La Jolla Pharmaceutical Company](#)

HQ Location: San Diego, CA

Product: Riquent

Dosage Form: Parenteral - Unspecified

Nature of API: Biologic - Protein

Therapeutic Area: Renal - Urology
Immunomodulator

Comment: La Jolla and collaborative partner BioMarin halts the development of Riquent for the treatment of lupus after the negative results of a Phase III interim analysis. Based on La Jolla's patented Tolerance Technology, the compound consists of a lupus disease-specific epitope attached to a carrier platform. The product suppresses the production of antibodies to double-stranded DNA in lupus patients and arrests or delays lupus renal disease without suppressing healthy functions of the immune system.

Manufacturing and packaging contact: [Josefina Elchico](#)

Manufacturing and packaging contact: [Luke Seikkula](#)

Clinical research contact: [Michael Tansey, MD, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [ViroPharma, Inc.](#)

HQ Location: Exton, PA

Product: CAMVIA (maribavir)

Dosage Form: Oral solid

Nature of API: Chemical - Normal potency

Therapeutic Area: Other
Antiviral

Comment: ViroPharma discontinues its Phase III trial of CAMVIA in liver transplant patients following the evaluation of Phase III results in stem cell transplant patients. The company's independent data monitoring committee also recommended the termination per the observed rate of viremia in

both arms of the study. CAMVIA is a benzimidazole compound.

- Research contact:** [Colin Broom, MD](#)
- Regulatory:** [Robert Pietrusko, PhD](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Filed

Export

Company: [Vion Pharmaceuticals Inc.](#)
HQ Location: New Haven, CT
Product: Onrigin (cloretazine)
Dosage Form: Parenteral - Unspecified
Nature of API: Chemical - Cytotoxic
Therapeutic Area: Oncology - Chemotherapy
Comment: Vion files an NDA for Onrigin for patients with relapsed acute myelogenous leukemia. Onrigin is an alkylating agent delivered as an injection. The company requested a priority review for the application, and, if it is granted, Onrigin could receive approval for this indication in H2 of 2009.

- Research contact:** [Ivan King, PhD](#)
- Clinical research contact:** [Ann Cahill](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Approved

Export

Company: [Takeda Pharmaceutical Company Limited](#)
HQ Location: [Multiple](#)
Product: ULORIC (febuxostat)
Dosage Form: Oral solid
Nature of API: Chemical - Normal potency
Therapeutic Area: Metabolic - Other
Comment: Takeda reports FDA approval for ULORIC for patients with chronic gout. ULORIC is a selective inhibitor of xanthine oxidase/dehydrogenase. ULORIC was discovered by Teijin Pharma and was licensed to Takeda for the US market.

- Corporate:** [Yasuchika Hasegawa](#)
- Research contact:** [Shigenori Ohkawa, PhD](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Marketed

Export

Company: [Johnson & Johnson Pharmaceutical R&D](#)
HQ Location: Raritan, NJ
Product: STELARA (ustekinumab)
Dosage Form: Parenteral - Unspecified

Nature of API: Biologic - Monoclonal antibody
Therapeutic Area: Dermatology
 Anti-inflammatory

Comment: Johnson & Johnson announces the launch of STELARA in Europe for the treatment of adults with moderate-to-severe plaque psoriasis. STELARA blocks interleukin-12 and interleukin-23, proteins that regulate the immune system and effect inflammatory disorders.

Sourcing and Supply Chain contact: [Julie Pedelini](#)
 Research contact: [Joanne Waldstreicher, MD](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Product Acquisitions & Alliances

Export

Buyer: [Novartis AG](#)
Seller: [Portola Pharmaceuticals](#)
Transaction Type: License
Product: Elinogrel (PRT060128)
Dosage Form: Parenteral - Unspecified
 Oral - Unspecified
Nature of API: Chemical - Normal potency
Therapeutic Area: Cardiovascular
 Antiplatelet
Development Phase: Phase II
Comment: Novartis acquires the worldwide license to develop and commercialize elinogrel, Portola's intravenous and oral P2Y12 ADP receptor antagonist currently in Phase II clinical development. Under the agreement, Portola will receive an upfront payment of \$75 million and up to \$500 million in milestones. Novartis will fund all future Phase III trials and share costs of ongoing and planned Phase II trials.
Annual Sales: \$0.00
 Clinical research contact: [Daniel D. Gretler, MD](#)
 Research contact: [David R. Phillips, PhD](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export

Alliance Partners: [Novelos Therapeutics, Inc.](#) [Mundipharma International, Ltd.](#)
Alliance Type: License
Product Name: NOV-002
Dosage Form: Parenteral - Unspecified
Nature of API: Chemical - Normal potency
Therapeutic Area: Oncology - Other
 Immunomodulator
Development Phase: Phase III
Description: Novelos signs an exclusive collaborative agreement with Mundipharma International to commercialize in Europe and

Asia/Pacific (excluding China) Novelos' lead compound, NOV-002, which is currently in a Phase III trial for non-small cell lung cancer. NOV-002 has also demonstrated positive results in Phase II trials for other cancer indications. Under the agreement, Novelos may receive up to \$25 million in milestones and \$60 million in fixed sales-based payments, plus royalties. Mundipharma will be responsible for certain development activities, regulatory submissions and commercialization of NOV-002 in the licensed territories. Novelos retains all rights and responsibilities in the US and the rest of the Americas.

Research contact: [Christopher Pazoles, PhD](#)

Clinical research contact: [Kirstin C. Schuhwerk](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Alliance Partners: [Romark Laboratories](#) [Chugai Pharmaceutical Co.](#)

Alliance Type: License

Product Name: Nitazoxanide (alinia)

Dosage Form: Oral solid

Nature of API: Chemical - Normal potency

Threapeutic Area: Anti-infective

Development Phase: Approved

Description: Romark and Chugai enter an exclusive license agreement to develop and commercialize nitazoxanide for chronic hepatitis C in Japan. Under the agreement, Romark will receive an upfront payment, clinical and regulatory milestone payments, profits from product sales in Japan through a supply agreement and royalties.

Corporate: [Celine Rossignol](#)

Research contact: [Jean-Francois Rossignol](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Corporate Finance, Alliances, and Acquisitions

Corporate Finance

Export

Company: [ActoGenix NV](#)

HQ Location: Zwijnaarde , Belgium

Financing Type: Venture capital investment

Amount Raised: \$17.26 million

Description: ActoGenix completes an equity financing round valued at over \$17.2 million. Proceeds will support ongoing and future clinical development programs as well as fund operations into 2011.

Strategy: ActoGenix develops therapies in various indications including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases based on its TopAct technology platform.

Corporate: [Mark Vaeck](#)

Research contact: [Bernard Coulie, MD, PhD](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export

Company: [Affymax, Inc.](#)

HQ Location: Palo Alto, CA

Financing Type: Private equity placement

Amount Raised: \$42.00 million

Description: Affymax receives \$42 million in a private placement. Proceeds will support the late-stage development of Hematide, a treatment for anemia.

Strategy: Affymax develops peptide drugs to treat cancer and immune-mediated diseases.

Clinical research contact: [Anne-Marie Duliege, MD](#)

Research contact: [Peter R. Young, PhD](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export

Company: [Cadence Pharmaceuticals](#)

HQ Location: San Diego, CA

Financing Type: Private equity placement

Amount Raised: \$86.60 million

Description: Cadence raises approximately \$86.6 million in a private placement. The use of proceeds was not disclosed.

Strategy: Cadence Pharmaceuticals (formerly Strata Pharmaceuticals) develops and commercializes pharmaceuticals utilized primarily in the hospital setting.

Manufacturing and packaging contact: [William S. Craig, PhD](#)

Clinical research contact: [Michael A. Royal, MD, JD](#)

Clinical research contact: [James B. Breitmeyer, MD, PhD](#)

Clinical research contact: [Catherine Hardalo, MD](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export

Company: [Divergence](#)

HQ Location: St. Louis, MO

Financing Type: Venture capital investment

Amount Raised: \$11.80 million

Description: Divergence raises \$11.8 million in a round of Series C financing. Proceeds will further Divergence's nematicide program and support its research platforms.

Strategy: Divergence discovers and develops products for the safe and effective control of parasites.

- Research contact:** [James McCarter](#)
- Preclinical contact:** [Deryck Jeremy Williams, PhD](#)
- Preclinical contact:** [Michael Crawford, PhD](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Galapagos](#)

HQ Location: Mechelen, Belgium

Financing Type: Government grant

Amount Raised: \$1.00 million

Description: Galapagos receives a \$1 million grant from the Flanders government. Galapagos will use the funds to progress the understanding of drug targets and accelerate the development of drug candidates for bone and joint diseases.

Strategy: Galapagos develops novel treatments for bone and joint diseases.

Research contact: [Graham Dixon, PhD](#)

Research contact: [Piet Wigerinck, PhD](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Geron Corporation](#)

HQ Location: Menlo Park, CA

Financing Type: Secondary public offering

Amount Raised: \$46.20 million

Description: Geron prices 7.25 million shares of common stock. This would raise approximately \$46.2 million at the current market price.

Strategy: Geron focuses on developing oncology and regenerative medicine products based upon its core technologies of telomerase, human embryonic stem cells and nuclear transfer.

Research contact: [Calvin B. Harley, PhD](#)

Research contact: [Melissa A. Kelly Behrs](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Helix BioMedix Inc.](#)

HQ Location: Bothell, WA

Financing Type: Private debt placement

Amount Raised: \$3.20 million

Description: Helix raises \$3.2 million through the sale of convertible promissory notes. The proceeds will be used for general corporate purposes, to initiate work towards product development and to support the continued expansion of the company's consumer program.

Strategy: Helix BioMedix develops bioactive lytic peptides for the treatment of bacterial, protozoan, and fungal infections, cancer, and the

promotion of wound healing.

Research contact: [Timothy Falla, PhD](#)

Corporate: [Robin Carmichael](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Human Genome Sciences, Inc.](#)

HQ Location: Rockville, MD

Financing Type: Milestone payment

Amount Raised: \$9.00 million

Description: Human Genome Sciences will receive a \$9 million milestone payment from GSK following GSK's initiation of a Phase III trial for Syncria, a treatment for type 2 diabetes mellitus. The company expects the payment in Q1 of 2009.

Strategy: Human Genome Sciences develops products for several therapeutic indications, including cancer, rheumatoid arthritis, lupus and hepatitis C.

Research contact: [David C. Stump, MD](#)

Corporate: [Curran Simpson](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Innate Pharma S.A.S.](#)

HQ Location: Marseille Cedex 09, France

Financing Type: Milestone payment

Amount Raised: Unknown

Description: Innate Pharma receives a milestone payment from Novo Nordisk due to the development of IPH 24 under a 2006 collaborative agreement for products to treat major chronic inflammatory conditions and autoimmune diseases.

Strategy: Innate Pharma develops products in the field of cancer immunotherapy.

Research contact: [François Romagné](#)

Clinical research contact: [Patrick Squiban](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Novelos Therapeutics, Inc.](#)

HQ Location: Newton, MA

Financing Type: Private equity placement

Amount Raised: \$10.00 million

Description: Novelos closes a \$10 million private placement of stock and warrants.

Strategy: Novelos focuses on oxidized glutathione-based compounds as treatments for cancer and hepatitis.

Research contact: [Christopher Pazoles, PhD](#)

Clinical research contact: [Kirstin C. Schuhwerk](#)

[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [Opsona Therapeutics](#)**HQ Location:** Dublin, Ireland**Financing Type:** Venture capital investment**Amount Raised:** \$23.00 million**Description:** Opsona raises \$23 million in a round of Series B financing. Proceeds will support operations and further Opsona's trials for inflammatory diseases.**Strategy:** Opsona Therapeutics develops drugs and vaccines to treat and prevent autoimmune and inflammatory diseases. **Corporate:** [Mark Heffernan](#) **Research contact:** [Andrew Parker](#)[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [Palatin Technologies Inc.](#)**HQ Location:** Cranbury, NJ**Financing Type:** Mixed financing**Amount Raised:** \$6.60 million**Description:** Palatin receives \$4.1 million from AstraZeneca due to the extension of an agreement to discover, develop and commercialize compounds that target melanocortin receptors and a clinical trial sponsored research agreement. Palatin will also receive a \$2.5 million milestone payment due to the collaboration with AstraZeneca.**Strategy:** Palatin develops biologics products using its MIDAS peptide platform, which streamlines the drug design process by identifying lead compounds from protein targets. **Corporate:** [Stephen T. Wills](#) **Research contact:** [Trevor Hallam, PhD](#)[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [Sequella](#)**HQ Location:** Rockville, MD**Financing Type:** Government grant**Amount Raised:** Unknown**Description:** Sequella receives a Small Business Innovation Research Phase I Grant from the NIH. Proceeds will further preclinical development of SQ609, a treatment for tuberculosis.**Strategy:** Sequella focuses on commercializing improved treatments for infectious diseases of epidemic potential. **Research contact:** [Leo Einck, PhD](#)

Preclinical contact: [Marina N. Protopopova, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Synta Pharmaceuticals](#)

HQ Location: Lexington, MA

Financing Type: Milestone payment

Amount Raised: \$10.00 million

Description: Synta receives a \$10 million milestone payment from GSK under its collaborative agreement for elesclomol.

Strategy: Synta focuses on drug discovery and development for cancer and autoimmune diseases.

Research contact: [James Barsoum, PhD](#)

Research contact: [Suresh R. Babu, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Vical, Inc.](#)

HQ Location: San Diego, CA

Financing Type: Milestone payment

Amount Raised: \$2.30 million

Description: Vical receives a \$2.3 million payment from AnGes MG following Vical's milestone achievement for Allovectin-7, which is in late-stage development.

Strategy: Vical develops and commercializes vaccines and immunotherapies based on its unique nonviral DNA technology.

Research contact: [Alain P. Rolland, PhD](#)

Research contact: [Larry R. Smith](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Corporate Alliances

Export

Alliance Partners: [Insmmed, Inc.](#) [Merck and Company, Inc.](#)

Description: Insmmed sells all assets related to its follow-on biologics platform to Merck for \$130 million. Insmmed's follow-on biologics assets include INS-19 and INS-20, whose development and commercial rights will now belong to Merck, as well as the Boulder, CO-based manufacturing facility. Merck intends to assume the facility's lease and ownership of all the equipment in the building. Merck also intends to offer positions to employees at the Boulder facility.

Research contact: [Peter S. Kim, PhD](#)

Manufacturing and packaging contact: [Willie A. Deese](#)

Manufacturing and packaging contact: [Doug Farrar](#)

Research contact: [Steve Glover](#)

[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Alliance Partners:** [MDRNA, Inc.](#) [Roche](#)**Description:** MDRNA enters into an agreement with Roche, in which Roche will obtain a non-exclusive license to a portion of MDRNA's technology platform for the development of RNAi-based therapeutics. Terms of the agreement were not disclosed. **Corporate:** [J. Michael French](#) **Corporate:** [William M. Burns](#) **Research contact:** [Jonathan Knowles, PhD](#) **Corporate:** [Bruce R. York](#)[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Alliance Partners:** [NeuroSearch A/S](#) [Eli Lilly and Company](#)**Description:** NeuroSearch and Eli Lilly enter a three-year discovery and development agreement to research treatments for disorders of the central nervous system. NeuroSearch will discover and conduct early development programs for new drug candidates, while Lilly will have options to exercise license rights for individual compounds. Eli Lilly will invest \$17 million in NeuroSearch, which is eligible to receive payments and research funding up to \$30 million and is entitled to milestone payments up to \$320 million as well as royalties. **Sourcing and Supply Chain contact:** [Joe Sutton](#) **Research contact:** [Frank Wätjen](#) **Preclinical contact:** [Jørgen Drejer](#) **Research contact:** [Thomas Verhoeven, PhD](#)[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#)

Other Sponsor Events

 Export**Sponsor:** [Amgen Inc.](#)**HQ Location:** Thousand Oaks, CA**Event Location:** North America**Strategy:** Amgen develops products based on advances in recombinant DNA and molecular biology.**Description:** Amgen contracts with Jones Lang LaSalle Americas to provide facilities management services that include: maintenance; food services; waste disposal and recycling; and inventory management. As a result, 150 Amgen current employees will be affected and given an opportunity

to interview for jobs with the new contractor or offered severance packages. The company also reports plans to reduce its engineering group.

Manufacturing and packaging contact: [Fabrizio Bonanni, PhD](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Export

Sponsor: [Bayer Schering Pharma AG](#)

HQ Location: Berlin, Germany

Event Location: Beijing, China

Strategy: Bayer Schering Pharma develops new medicines and therapies.

Description: Bayer reports that it will build an R&D center in Beijing over the next five years. The company expects to spend about \$129 million for the facility.

Clinical research contact: [Kemal Malik, MD](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Export

Sponsor: [Ferring Pharmaceuticals, Inc.](#)

HQ Location: Saint-Prex, Switzerland

Event Location: San Diego, CA

Strategy: Ferring Pharmaceuticals discovers, develops and markets biologics, peptides and proteins with three core therapeutic areas: infertility, urology and gastroenterology.

Description: Ferring and its affiliate, Ferring Research Institute, open an expanded, 38,000-square-foot facility in Sorrento Valley, San Diego. The site will focus on the development of peptide research and therapeutics.

Clinical research contact: [Pascal Danglas](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Export

Sponsor: [Novogen Ltd.](#)

HQ Location: [Multiple](#)

Event Location: Worldwide

Strategy: Novogen uses its isoflavonoid technology platform to treat degenerative diseases.

Description: Novogen implements its cost reduction measures including outsourcing of the scale-up manufacturing of compounds in clinical development; putting cardiovascular and anti-inflammatory programs on hold; reducing its staff from 62 to 51 employees; and implementing fee and income reductions of 20% for the board members and executive team.

Research contact: [Alan J. Husband, PhD](#)

[Print Lead](#) [Email Lead](#)

[\[Back to Top\]](#)

Export

Sponsor: [Oscient Pharmaceuticals Corporation](#)
HQ Location: Waltham, MA
Event Location: US
Strategy: Oscient develops antibacterial pharmaceutical products.
Description: Oscient will reduce its workforce by approximately 32%, leaving the company with 205 employees across the US.

Clinical research contact: [Inder Kaul, MD](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export

Sponsor: [Telik, Inc.](#)
HQ Location: Palo Alto, CA
Event Location: Palo Alto, CA
Strategy: Telik develops and commercializes small molecule drugs to treat serious disease.
Description: Telik reduces its workforce by 44%, primarily in early-stage discovery and support positions.

Corporate: [Michael M. Wick, MD, PhD](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export

Sponsor: [Teva Pharmaceutical Industries Ltd.](#)
HQ Location: Petach Tikva, Israel
Event Location: Worldwide
Strategy: Teva Pharmaceutical Industries develops, manufactures and markets generic and innovative human pharmaceuticals and APIs.
Description: Teva lays off 1,000 or more employees worldwide as part of its acquisition of Barr Pharmaceuticals.

Corporate: [William Marth](#)

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Key Appointments

Export

Company: [AlphaVax, Inc.](#)
HQ Location: Research Triangle Park, NC
Appointee: Lynn Baird, PhD
Position: VP, Regulatory, Quality & Clinical Operations.

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export

Company: [AspenBio Pharma, Inc.](#)
HQ Location: Castle Rock, CO
Appointee: Robert Caspari, MD
Position: COO & CMO

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export **Company:** [F2G Ltd.](#)
HQ Location: Manchester, UK
Appointee: Tony Kennedy
Position: Chief Scientific and Development Officer

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export **Company:** [Pharmaxis](#)
HQ Location: [Multiple](#)
Appointee: Howard Fox
Position: CMO

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export **Company:** [Pluristem Therapeutics, Inc.](#)
HQ Location: Haifa, Israel
Appointee: Frida Grynspan, PhD
Position: VP, R&D

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)

Export **Company:** [Sanofi-aventis](#)
HQ Location: [Multiple](#)
Appointee: Jean-Pierre Lehner
Position: CMO

[Print Lead](#) [Email Lead](#) [\[Back to Top\]](#)
